{
    "nctId": "NCT01075802",
    "briefTitle": "Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms",
    "officialTitle": "A Multi-Centre Study of Tamoxifen Dose Escalation Study in Breast Cancer Patients With CYP2D6 Polymorphisms",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, CYP2D6 Polymorphism",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 121,
    "primaryOutcomeMeasure": "Effects of genotype of CYP2D on plasma and serum concentration of tamoxifen and its metabolites, with consequent recommendation for dosage adjustment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* ECOG performance status \u2264 1\n* Life expectancy \u2265 6 months\n* Histologically or cytologically confirmed early, locally advanced or metastatic breast cancer\n* Oestrogen receptor positive\n* About to start tamoxifen treatment or already on tamoxifen 20mg daily\n* Adequate hepatic and renal function\n\nExclusion Criteria:\n\n* Concurrent chemotherapy or radiotherapy\n* Treatment with medications that may alter cytochrome P450 (CYP450)3A4/5 and CYP2D6 activities\n* History of thrombosis\n* History of non-compliance with previous or current treatment;\n* Medical or psychiatric conditions that compromise the patient's ability to give informed consent",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}